氢化可的松(Hydrocortisone) - 药物靶点：GR_在研适应症：先天性肾上腺增生，孤立性ACTH缺乏症，肾上腺皮质功能不全_专利_临床

概要

基本信息

简介氢化可的松是一种小而强大的分子，以其作为糖皮质激素受体 (GR) 激动剂的能力而闻名，从而刺激 GR。该药物具有广泛的临床应用，通常用于治疗与肾上腺功能不全密切相关的多种疾病，包括但不限于先天性肾上腺增生、肾上腺增生、艾迪生病和孤立性促肾上腺皮质激素缺乏症。此外，它已被证明可有效治疗亚急性甲状腺炎、溃疡性结肠炎、直肠结肠炎和溃疡性直肠炎等炎症。值得注意的是，FDA 最初于 1952 年 8 月 5 日批准了氢化可的松。氢化可的松的开发归功于该药物的先驱 Merck Sharp & Dohme Corp。由于其非凡的抗炎和免疫抑制特性，氢化可的松已成为许多慢性炎症性疾病的最终药物。

药物类型

小分子化药

别名

(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione、11beta,17alpha,21-Trihydroxy-4-pregnene-3,20-dione、11beta-hydrocortisone

+ [60]

靶点

GR

作用方式

激动剂

作用机制

GR激动剂(糖皮质激素受体激动剂)

治疗领域

肿瘤免疫系统疾病感染+ [10]

在研适应症

先天性肾上腺增生孤立性ACTH缺乏症肾上腺皮质功能不全+ [20]

非在研适应症

淋巴母细胞淋巴瘤重度抑郁症复发性儿童急性淋巴细胞白血病+ [2]

原研机构

Merck Sharp & Dohme Corp.

在研机构

ANI Pharmaceuticals, Inc.

Pfizer Japan, Inc.

Eton Pharmaceuticals, Inc.

+ [4]

非在研机构

Takeda Pharmaceutical Co., Ltd.

Merck & Co., Inc.

Shire Plc

+ [1]

权益机构

TOLMAR Holding, Inc.EffRx, Inc.

ExCEEd Orphan sro

+ [8]

最高研发阶段批准上市

首次获批日期

美国 (1952-08-05),

内分泌系统疾病超敏反应免疫系统疾病+ [1]

最高研发阶段(中国)批准上市

特殊审评快速通道 (美国)、孤儿药 (美国)、孤儿药 (欧盟)、孤儿药 (澳大利亚)

登录后查看时间轴

结构/序列

分子式C21H30O5

InChIKeyJYGXADMDTFJGBT-VWUMJDOOSA-N

CAS号50-23-7

关联

250

项与氢化可的松相关的临床试验

NCT06892197

/ Not yet recruiting临床4期IIT

Comparing Hydrocortisone and Prednisolone for Community Acquired Pneumonia (CAP)

The goal of this cluster randomized controlled trial is to determine the optimal treatment for community aquired pneumonia (CAP). The study compares the effects and side effects of hydrocortisone and prednisolone in patients above 18 years old diagnosed with severe CAP. The main question is whether there is a difference in all cause mortality within thirty days.
Participants will be randomized to receive treatment with either hydrocortisone or prednisolone.

开始日期2025-08-01

申办/合作机构-

NCT06892210

/ Not yet recruiting临床4期IIT

Comparing Hydrocortisone and Prednisolone for Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)

The goal of this cluster randomized controlled trial is to determine the optimal treatment for Acute Exacerbation of Chronic Obstructive Pulmonary Disease. The study compares the effects and side effects of hydrocortisone and prednisolone in patients above 40 years old diagnosed with chronic obstructive pulmonary disease with acute exacerbation. The main question is whether there is a difference in readmission for COPD excerbation or all cause mortality within thirty days.
Participants will randomized to receive treatment with either hydrocortisone or prednisolone.

开始日期2025-08-01

申办/合作机构-

NCT06317662

/ Recruiting临床2期IIT

A Phase 2 Study of Blinatumomab in Combination With Chemotherapy for Infants With Newly Diagnosed Acute Lymphoblastic Leukemia With Randomization of KMT2A-Rearranged Patients to Addition of Venetoclax

This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged [R]) or without a KMT2A gene rearrangement (KMT2A-germline [G]). Venetoclax is in a class of medications called B-cell lymphoma-2 (Bcl-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Blinatumomab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding venetoclax and/or blinatumomab to standard chemotherapy may be more effective at treating patients with ALL than standard chemotherapy alone, but it may also cause more side effects. This clinical trial evaluates the safety and effectiveness of adding venetoclax and/or blinatumomab to chemotherapy for the treatment of infants with KMT2A-R or KMT2A-G ALL.

开始日期2025-06-05

申办/合作机构

National Cancer Institute

100 项与氢化可的松相关的临床结果

登录后查看更多信息

100 项与氢化可的松相关的转化医学

登录后查看更多信息

100 项与氢化可的松相关的专利（医药）

登录后查看更多信息

90,196

项与氢化可的松相关的文献（医药）

2025-12-31·Italian Journal of Animal Science

A comparative study to estimate three commercial products of human chorionic gonadotropin (hCG) on blood biochemistry, sexual hormones concentrations, reproductive indices, and larvae production of African catfish Clarias gariepinus brood-stock

作者: Ahmed, Mohammad Z. ; Abdel-Aziz, Mohamed F. A. ; Saleh, Hamed H. E. ; Attia, El-Sayed I. ; Arai, Takaomi ; Hassan, Habib Ul

Hormonal induction is an effective method for spawning African catfish, especially the use of human chorionic gonadotropin (hCG)Hormonal treatment is an essential factor in the cost of seed productionThere are many types of hCG products used in Egypt but Choriomon is the best in efficiency of reproduction and economic

2025-12-31·Gut Microbes

Gut dysbiosis-induced vitamin B6 metabolic disorder contributes to chronic stress-related abnormal behaviors in a cortisol-independent manner

Article

作者: Chen, Huimin ; Tong, Jianhua ; Duan, Kaiming ; Tong, Jianbin ; Chen, Jie ; Ma, Xin ; Ouyang, Wen ; Chen, Hui ; Qing, Wenxiang ; Ma, Daqing ; Le, Yuan

Chronic stress can result in various conditions, including psychological disorders, neurodegenerative diseases, and accelerated brain aging. Gut dysbiosis potentially contributes to stress-related brain disorders in individuals with chronic stress. However, the causal relationship and key factors between gut dysbiosis and brain disorders in chronic stress remain elusive, particularly under non-sterile conditions. Here, using a repeated restraint stress (RRS) rat model, we show that sequential transplantation of the cecal contents of different RRS stages to normal rats reproduced RRS-induced core phenotypes, including abnormal behaviors, increased peripheral blood corticosterone and inflammatory cytokines, and a unique gut microbial phenotype. This core phenotypic development was effectively inhibited with probiotic supplement. The RRS-induced unique gut microbial phenotypes at the genus level were positively or negatively associated with the levels of 20 plasma metabolites, including vitamin B6 metabolites 4-pyridoxic acid and 4-pyridoxate. Vitamin B6 supplement during RRS alleviated weight loss, abnormal behaviors, peripheral inflammation, and neuroinflammation, but did not affect the peripheral corticosterone levels in chronic stressed rats. Dampening inflammatory signaling via knocking out caspase 11 or caspase 1 inhibitor abolished RRS-induced abnormal behaviors and peripheral and neuroinflammation but did not decrease peripheral corticosterone in mice. These findings show that gut dysbiosis-induced vitamin B6 metabolism disorder is a new non-hypothalamic-pituitary-adrenal axis mechanism of chronic stress-related brain disorders. Both probiotics and vitamin B6 supplement have potential to be developed as therapeutic strategies for preventing and/or treating chronic stress-related illness.

2025-12-31·STRESS-THE INTERNATIONAL JOURNAL ON THE BIOLOGY OF STRESS

Differences in hair cortisol to cortisone ratio between depressed and non-depressed adolescent women

Article

作者: Garel, Patricia ; Herba, Catherine M. ; Porter-Vignola, Elyse ; Marin, Marie-France ; Zerroug, Yasmine

Research on stress has demonstrated that the hypothalamic-pituitary-adrenal (HPA) axis contributes to major depressive disorder in youth. Hair glucocorticoids are key biological markers of chronic stress. We assessed group differences in hair cortisol and cortisone concentrations, and the cortisol/cortisone ratio between depressed adolescent women and a non-depressed comparison group. Further, within the depression group, we explored the contribution of symptom severity and clinical correlates of depression in relation to glucocorticoid concentrations. Hair samples of three centimeters for 74 adolescent women (41 in the depression group and 33 in the comparison group), aged between 12 and 19 years old, were analyzed. Depressive and anxiety symptoms were measured using the Beck Youth Inventory II and clinical correlates of depression were measured using the Childhood Trauma Questionnaire-Short Form and the Borderline Personality Features Scale for Children. No significant differences emerged between the depression group and the comparison group on hair cortisol or hair cortisone concentrations. However, groups differed significantly on the cortisol/cortisone ratio, a proposed proxy of 11-beta-hydroxysteroid dehydrogenase activity, with a higher ratio for the depression group. Within the depression group, neither symptom severity nor clinical correlates were associated with glucocorticoid concentrations. Although cross-sectional, our findings highlight the importance of future studies to test whether the group difference found in cortisol/cortisone ratio is the result of alterations in 11-beta-hydroxysteroid dehydrogenase enzymes (type 1 or 2) activity. Further research is thus needed to clarify the role of these enzymes in major depressive disorder in youth and to develop more targeted intervention strategies.

181

项与氢化可的松相关的新闻（医药）

2025-06-22

·米内网

44个品种集采来袭！4亿市场迎洗牌，26个高端注射剂被盯上，华润、远大、倍特优势十足

精彩内容近期，集采消息频传：第三批中成药集采全国落地，新疆26省联盟集采报量在即，浙江拟启动第六批药品集采；江苏44个品种接续集采来袭，不乏桉柠蒎口服常释剂型等独家大单品（含剂型独家，下同），以及亮丙瑞林（缓释）微球注射剂等2024年在江苏省公立医院终端销售额超1亿元的临床畅销药。2025年过近半，第十一批国采如箭在弦，拟纳入品种目录有望于近日出炉；省采/省联采稳步推进，安徽、四川、新疆等地先后牵头启动，涉及生物药、造影剂、妇科类、激素类等多个药品领域。品种中选规则温和，区分是否独家拟定采购量今年6月，江苏省医保局发布《江苏省第一、二、三轮集采药品接续采购方案（征求意见稿）》，意味着江苏新一轮接续集采工作正式拉开序幕。来源：江苏省医保局据悉，此次接续集采涉及三个批次、共计44个品种（按通用名统计，下同），其中第一批有5个品种，第二批有2个品种，第三批有37个品种。采购周期原则上为两年，在采购周期内，如中选药品已纳入国采，则执行国采结果。集采中选规则较为温和，主要以江苏省上一轮集采中选价格为参考，即：①有省级集采中选（备选）记录产品，报价≤同品种本省上一轮集采中选最高价的，拟中选；②无省级集采中选（备选）记录产品，若为参比制剂、原研药、已过评的通用名药，报价≤同品种本省上一轮集采中选最高价的，拟中选；若为未过评的同通用名药，报价≤同品种本省上一轮集采中选平均价的，拟中选。此外，未中选产品或新获批产品也可补充中选，但无法参与集采分量。意向采购量分配上，中选产品按以下规则分配给中选企业：①独家品种在省级集采最低价省份中选的，带同品种意向采购量；而备选的则仅中选不带量，若降价至所有独家品种拟中选企业平均降幅时，带意向采购量；②非独家品种中选价由低至高排名前50%的企业，将获得医疗机构对其所报意向采购量作为优先量，再按上一年度招采系统验收量大的、挂网价低的次序确定优先量企业。总体而言，本次接续集采采购量分配规则基本沿用此前江苏第五批集采的相应规则，根据品种是否独家确认采购量，针对非独家品种，将未中选企业和其余中选企业所报意向采购量作为剩余量分配给中选产品。4亿市场格局重塑，华润、远大......优势十足此次江苏省接续集采拟纳入44个品种，其中医保甲类药有6个，医保乙类药有35个，非医保用药有3个；从剂型上看，注射剂为主力军，占26个席位；按治疗大类统计，消化系统及代谢药以11个产品在数量上领跑，血液和造血系统药物、全身用抗感染药物分别有8个和5个产品在列。拟纳入江苏省接续集采药品清单来源：江苏省医保局，米内网整理44个拟纳入集采的品种中，既有蛇毒血凝酶注射剂、桉柠蒎口服常释剂型等独家大单品，也有亮丙瑞林（缓释）微球注射剂、氟比洛芬贴剂等2024年在江苏省公立医院终端销售额超4000万元的临床畅销药，以及天麻素注射剂、氢化可的松乳膏剂等销售额增速达三位数的潜力品种。桉柠蒎口服常释剂型属于黏液溶解性祛痰药，适用于急/慢性鼻窦炎、急慢性支气管炎等呼吸道疾病，亦可用于促进支气管造影术后造影剂的排出。作为国家基药、医保乙类药品种，桉柠蒎肠溶软胶囊2024年在江苏省公立医院终端销售额约800万元，同比增长18.57%，目前仅远大医药拥有该药生产批文。近年来江苏省公立医院终端桉柠蒎口服常释剂型销售趋势（单位：万元）来源：米内网重点省市公立医院药品终端竞争格局亮丙瑞林（缓释）微球注射剂用于子宫内膜异位症、子宫肌瘤、乳腺癌、前列腺癌、中枢性性早熟等疾病治疗，2024年在江苏省公立医院终端销售额首破1亿元，同比涨逾10%。米内网数据显示，目前该品种有2款制剂获批上市，其中注射用醋酸亮丙瑞林微球有武田药品、丽珠医药（首家过评）拥有生产批文，浙江圣兆药物以新分类报产在审，北京博恩特药业提交一致性评价补充申请在审；注射用醋酸亮丙瑞林缓释微球仅北京博恩特药业拥有生产批文，为本品首仿产品。亮丙瑞林（缓释）微球注射剂一致性评价申报情况来源：米内网一致性评价进度数据库天麻素注射剂用于神经衰弱、神经衰弱综合征及血管神经性头痛，亦可用于脑外伤性综合征、药性眩晕等，目前已纳入全国医保乙类药目录。在江苏省公立医院终端，该品种2024年销售额增速达惊人的586.87%，从企业格局上看（按一级集团统计），华润医药以超50%的市场份额遥遥领先，倍特药业（约36%）、远大健康（约11%）等位居其后。2024年江苏省公立医院终端天麻素注射剂一级集团格局来源：米内网重点省市公立医院药品终端竞争格局在重点省市公立医院终端，江苏省2020-2024年销售规模均在145亿元以上，2024年拿下近五年的历史新高超154亿元，同比增长3.02%；本次接续集采拟纳入44个品种，2024年在江苏省公立医院终端的合计销售额接近4亿元。江苏省公立医院终端销售规模（单位：亿元）来源：米内网重点省市公立医院药品终端竞争格局新一批国采如箭在弦，地方集采稳步推进近日，业内传出一份《关于征求<第十一批国家组织药品集中采购拟采购药品清单>意见的函》（下文简称《清单》），75个品种或纳入第十一批国采。不过，《清单》仅为网传版本，一切以官方发布为准。据不完全统计，截至6月20日，至少有140余个品种未纳入国采且满足7家及以上的企业竞争格局，初步具备纳入第十一批国采的条件。从剂型分布上看，注射剂仍是主力，涉及注射用头孢唑肟钠、法莫替丁注射液、二羟丙茶碱注射液等热门品种，涵盖全身用抗感染药物、消化系统及代谢药及呼吸系统用药等多个治疗大类。140余个品种2024年在中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院（简称中国公立医疗机构）终端销售规模合计超过840亿元，其中33个品种竞争激烈，参与竞争企业数（按集团计，下同）达15家及以上。140余个品种中，涉及过评品种数达20个及以上的企业有7家，包括倍特药业、科伦药业、齐鲁制药、正大制药、石家庄四药等国内知名药企。地方层面上，今年以来已有多个省（市、自治区）牵头启动省级/省联盟药品集采，各地集采工作正稳步推进中。6月18日，新疆省医保局发布的《关于开展二十六省联盟药品集中带量采购报价及议价工作的通知》显示，新疆牵头26省联盟集采将于下周四（6月26日）启动报价，下周五（6月27日）10-14时开展议价。届时，42个拟集采品种（按产品品规计）的市场格局将加速重塑，涉及造影剂、妇科、激素等多个专科领域大品种。来源：新疆省医保局今年5月，四川组建的6省联盟集采结果出炉，共有241家企业的66个品种、376个品规拟中选。其中，石家庄四药、国药集团、科伦药业等企业拟中选品规均在5个及以上，肌苷注射剂、氯诺昔康注射剂、单硝酸异山梨酯注射剂等产品降幅超90%。今年2月，安徽官宣将牵头开展全国生物药联盟集采，贝伐珠单抗注射液、聚乙二醇化重组人粒细胞刺激因子注射液、人促红素注射液等成大热选手，其2024年在中国公立医疗机构终端销售额分别超100亿元、38亿元和27亿元。结语今年以来，国家曾多次发文明确：要求优化药品和耗材集采机制，强调质量监管与创新支持并重；当前已形成“国家+联盟”的双轨采购格局，预计今年内完成第十一批药品集采，并推动集采品种突破700个的大关。在价格挤压与质量管控的双重压力下，药品行业正经历结构性的重塑。资料来源：米内网数据库、江苏省医保局等注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；米内网重点省市公立医院化学药终端竞争格局数据库是以20+省市，近700家样本省市公立医院的化学药采购数据为基础，对化学药全品类进行连续监测的样本省市样本医院数据库；上述销售额以产品在终端的平均零售价计算。数据统计截至6月20日，如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

带量采购

2025-06-16

·PRNewswire

Cortizone-10® Partners with Dylan Efron and the National Park Foundation to Help Outdoor Enthusiasts Stay Itch-Free This Summer

The brand's new Itch Relief Cooling Spray helps tackle "itchsanity" one irritation at a time. MORRISTOWN, N.J., June 16, 2025 /PRNewswire/ -- Whether it's a weekend hike, a summer camping trip, or just time spent in the backyard, skin irritations can take the fun out of outdoor activities. That's why Cortizone-10®, the #1 Doctor Recommended OTC Topical Anti-Itch Brand*, is teaming up with the National Park Foundation and outdoor advocate Dylan Efron this summer to help more people enjoy nature—without the itch. Continue Reading Dylan Efron with Cortizone-10® Itch Relief Cooling Spray | Photo Credits: brennensmedia Cortizone-10® Itchy Bear Season To enjoy nature without the not-so-great itches, we need to make sure there are outdoor spaces worth enjoying–so Cortizone-10® is partnering with the National Park Foundation, providing $475K as part of a broader brand initiative, to help protect wildlife, preserve habitats, and support conservation efforts across some of the country's most iconic and ecologically rich landscapes. To help amplify the campaign, Dylan Efron—actor, producer, and lifelong outdoor enthusiast—is partnering with Cortizone-10®, an Opella brand, to share his favorite summer adventures and how he doesn't let itches get in the way. "Ever since I was a little kid, I've always loved being outside—all day, every day," said Dylan Efron. "That's why I am so excited to partner with Cortizone-10®. I can't even count how many times I've used this stuff in a year—let alone over my lifetime. Bug bites, poison ivy, poison oak...been there, scratched that. But no itch has ever kept me from enjoying everything the outdoors has to offer." The partnership celebrates the launch of Cortizone-10® 's new Itch Relief Cooling Spray, designed to provide fast, cooling itch relief of common skin irritations that may arise from eczema and psoriasis to bug bites and poison ivy. "We're thrilled to be teaming up with Dylan Efron and the National Park Foundation for a campaign that celebrates adventuring itch-free," said Nimit Bansal, Cortizone-10® Marketing Lead. "Cortizone-10® has always been trusted itch relief for bug bites, eczema, poison ivy, and more—and now, we're making it easier than ever for people to enjoy the outdoors without the itch getting in the way." As part of its broader "Itchsanity" campaign, Cortizone-10® is launching Itchy Bear Season, a social-first series that spotlights different "itchy bear" types one might run into in the great outdoors and shares practical tips on how to stay itch-free outside. A playful nod to natural behaviors seen in the wild, the campaign reminds us that everyone itches—but with Cortizone-10®, you don't have to suffer through it. Visit @cortizone10 on Instagram to cast your vote for itchiest bear in the brand's first-ever Big Bear Itch Off competition and follow along to learn more. The new Cortizone-10® Itch Relief Cooling Spray is available now at drugstores and major retailers nationwide. Learn more at Cortizone10.com. *2024 IQVIA Study About Cortizone-10® Cortizone-10® is the #1 Doctor Recommended OTC Topical Anti-Itch Brand*, trusted for fast, effective relief from itch and irritation. Featuring the maximum strength of hydrocortisone available without a prescription, Cortizone-10® products are specially formulated to calm and soothe a wide range of itchy skin discomforts—including bug bites, poison ivy, eczema, psoriasis, and rashes caused by soaps, detergents, and cosmetics. With a variety of formats like creams, ointments, and sprays, Cortizone-10® delivers targeted, long-lasting relief to help people get back to feeling comfortable—so they can stay focused on what matters most. About Opella Opella is the self-care challenger with the purest and third-largest portfolio in the Over-The-Counter (OTC) & Vitamins, Minerals & Supplements (VMS) market globally. Our mission is to put health in people's hands by making self-care as simple as it should be for over half a billion consumers worldwide. At the core of this mission is our 100 brands, our 11,000-strong global team, our 13 best-in-class manufacturing sites and four specialized science and innovation development centers. Headquartered in France, Opella is the proud maker of many of North America's most loved brands, including Allegra®, Dulcolax®, Icy Hot®, Xyzal®, Unisom® and Cortizone-10®. B Corp certified in multiple markets, we are active players in the journey towards healthier people and planet. Find out more about our mission at . SOURCE Cortizone-10® WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2025-06-14

·赛柏蓝

157个品种，带量采购（附名单）

作者 | 陈芋责编 | 遥望关注赛柏蓝，主页“发消息”对话框回复0613获取以下采购清单excel/pdf等文件0142个品种，26省带量采购近日，新疆医保局发布《二十六省联盟药品集中带量采购文件》，正式启动新一轮联盟采购。该联盟由新疆牵头，北京、天津、山西、内蒙古、辽宁、吉林、黑龙江、安徽、福建、江西、河南、湖北、湖南、广西、海南、重庆、四川、贵州、云南、西藏、陕西、甘肃、青海、宁夏、新疆及兵团共26省（自治区/直辖市，下同）参与。联盟省内所有公立医疗机构（含军队医疗机构）全部参加集中采购，同时还应引导医保定点社会办医疗机构和零售药店参加。此次采购主要针对国采范围之外的品种，以过评仿制药合计7家以下的品种为前提，纳入碘美普尔、醋酸甲地孕酮、醋酸甲羟孕酮等42个品种（完整名单见文末附1），覆盖妇科及激素类、造影剂等重点产品。采购周期自中选结果执行之日起至2027年12月31日。新疆及兵团在文件中明确，本次集采流标品种将按照规定纳入重点监测范围，对其在定点医药机构的采购和使用情况加强监测和管理。报价方面，以企业同一竞价单元中所有申报品种的省级医药采购平台最低挂网价（含集采中选价）按差比价规则折算至采购品种目录基准规格最小计量单位，取最低值作为最高有效申报价。联盟省内均无省级医药采购平台挂网价的，取同竞价单元所有投标企业最高有效申报价的均价为该企业最高有效申报价。报价、综合评审、议价谈判等将分为A、B两组进行，原研、参比制剂、过评药品等列为A组，其他药品列为B组。产品得分由报价分、降幅分、医药机构覆盖情况组成，最多11家企业入围。同竞价单元有效申报企业数为1家的，归入独家分组，通过谈判议价确定拟中选企业。0244个品种，带量采购流标独家品种将被重点监测近日，江苏省医保局发布《关于公开征求省第一、二、三轮集采药品接续采购方案意见的公告》，对江苏省第一、二、三轮集采药品中未纳入国家集采和国家价格风险处理范围的品种展开采购，涉及烟酰胺、达肝素钠、亮丙瑞林（缓释）微球、氢化可的松等44个品种（完整名单见文末附2），接续采购周期为2年。此次接续中，有省级集采中选（备选）记录产品，报价不高于同品种江苏上一轮集采中选最高价的，拟中选。无省级集采中选（备选）记录产品，参比制剂、原研药、过评的同通用名药，报价不高于同品种江苏上一轮集采中选最高价的，拟中选；未过评的同通用名药，报价不高于同品种江苏上一轮集采中选平均价的，拟中选。若独家品种流标，其将在平台予以单独标识，采购情况纳入重点监测范围并定期通报，采购流标独家品种金额排名靠前的公立医疗机构将予以约谈。当非独家品种出现流标情况，江苏将增加一轮竞价，同品种所有参与企业合为一组进行竞价，由专家研究制定最高有效申报价，有效报价中价格最低的1家企业拟中选，最低报价企业2家及以上时，则优先2024年度省招采子系统采购量大的企业。重新竞价后仍然流标的非独家品种，同品种近1个月有省招采子系统采购验收记录的挂网企业中，价格最低的1家拟中选，其余企业在采购周期内暂停挂网。0371个品种中选结果即将落地6月13日，陕西对17省（区、兵团）药品联盟协议采购量分配工作启动。该联盟由河南牵头，包括河南、江西、山西、内蒙古、黑龙江、湖北、湖南、广西、海南、重庆、贵州、云南、陕西、青海、宁夏、新疆、新疆生产建设兵团共17省。联盟采购覆盖阿昔莫司、复方利血平、卡格列净等71个品种，共产生500余个中选结果，涉及271家生产企业（中选价格供应清单等见文末附3）。按照文件，分配采购量=医疗机构需求量*(本品种最低中选价/本企业中选价)；待分配采购量=该品种医疗机构需求量-该品种分配采购量；各品种待分配采购量由医疗机构在中选产品中自主选择分配，鼓励医疗机构优先选择质优价宜的中选产品。陕西的分量系统在6月19日前保持开放，逾期未完成分配的医疗机构的待分配量由系统自动平均分配给价格最低的中选产品。关注赛柏蓝，主页“发消息”对话框回复0613获取以下采购清单excel/pdf等文件附1：附2：附3：受篇幅限制，此处仅附部分供应清单，完整清单可关注赛柏蓝，后台对话框回复0613获取文件下载END内容沟通：郑瑶（13810174402）

带量采购一致性评价

100 项与氢化可的松相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00088	氢化可的松	D07AA02 A01AC03 S02BA01	DB00741

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
先天性肾上腺增生	欧盟	Neurocrine Biosciences, Inc.	2021-05-27
先天性肾上腺增生	冰岛	Neurocrine Biosciences, Inc.	2021-05-27
先天性肾上腺增生	列支敦士登	Neurocrine Biosciences, Inc.	2021-05-27
先天性肾上腺增生	挪威	Neurocrine Biosciences, Inc.	2021-05-27
孤立性ACTH缺乏症	日本	Pfizer Japan, Inc.	1972-12-21
肾上腺皮质功能不全	日本	Pfizer Japan, Inc.	1972-12-21
感染	日本	Pfizer Japan, Inc.	1972-12-21
亚急性甲状腺炎	日本	Pfizer Japan, Inc.	1972-12-21
溃疡性结肠炎	美国	ANI Pharmaceuticals, Inc.	1966-01-12
直肠结肠炎	美国	ANI Pharmaceuticals, Inc.	1966-01-12
溃疡性直肠炎	美国	ANI Pharmaceuticals, Inc.	1966-01-12
过敏	美国	Pharmacia & Upjohn, Inc.	1952-12-15
胶原蛋白疾病	美国	Pharmacia & Upjohn, Inc.	1952-12-15
水肿	美国	Pharmacia & Upjohn, Inc.	1952-12-15
眼部疾病	美国	Pharmacia & Upjohn, Inc.	1952-12-15
胃肠道疾病	美国	Pharmacia & Upjohn, Inc.	1952-12-15
血液疾病	美国	Pharmacia & Upjohn, Inc.	1952-12-15
肿瘤	美国	Pharmacia & Upjohn, Inc.	1952-12-15
呼吸系统疾病	美国	Pharmacia & Upjohn, Inc.	1952-12-15
风湿性疾病	美国	Pharmacia & Upjohn, Inc.	1952-12-15

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
21-羟化酶缺乏症引起的先天性肾上腺皮质增生	临床3期	美国	-	2018-10-04
艾迪生病	临床2期	德国	-	2021-11-23
艾迪生病	临床2期	英国	-	2021-11-23
淋巴母细胞淋巴瘤	临床1期	美国	Takeda Pharmaceutical Co., Ltd.	2019-03-25
复发性儿童急性淋巴细胞白血病	临床1期	美国	Takeda Pharmaceutical Co., Ltd.	2019-03-25
复发难治性急性淋巴细胞白血病	临床1期	美国	Takeda Pharmaceutical Co., Ltd.	2019-03-25
难治性成人急性淋巴细胞白血病	临床1期	美国	Takeda Pharmaceutical Co., Ltd.	2019-03-25
重度抑郁症	临床阶段不明	美国	Wyeth AB	2002-08-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05063994 (CONnECT, CTgov)	临床3期	先天性肾上腺增生 \| 21-羟化酶缺乏症引起的先天性肾上腺皮质增生	55	Placebo+Chronocort (Chronocort)	築範獵鏇獵鏇襯壓壓鬱 = 醖鬱廠顧膚齋餘壓夢襯觸憲糧獵醖膚窪齋憲鬱 (齋夢壓選糧製淵衊顧簾, 夢網壓獵鹽鹹繭遞遞糧 ~ 範窪觸積廠夢淵鏇夢醖) 更多	-	2025-02-24
				Placebo+Cortef (Cortef)	築範獵鏇獵鏇襯壓壓鬱 = 鹹餘構艱願鹽鹹顧襯築觸憲糧獵醖膚窪齋憲鬱 (齋夢壓選糧製淵衊顧簾, 顧蓋壓範衊遞廠構膚積 ~ 選鬱構膚顧糧憲襯選製) 更多
NCT02997605 (STAR, Pubmed \| Ann Rheum Dis)	临床3期	类风湿关节炎	102	Hydrocortisone replacement	蓋簾襯淵蓋壓選蓋壓衊(憲遞鹹壓壓窪蓋繭鬱蓋) = 構鏇蓋顧觸憲簾製遞醖築襯鹹淵餘膚繭鏇衊襯 (醖鹹淵顧簾壓餘窪積鑰 )	不佳	2024-10-29
				Prednisone tapering	蓋簾襯淵蓋壓選蓋壓衊(憲遞鹹壓壓窪蓋繭鬱蓋) = 蓋築顧齋獵鬱憲鏇範糧築襯鹹淵餘膚繭鏇衊襯 (醖鹹淵顧簾壓餘窪積鑰 )
NCT03832010 (CTgov)	临床4期	湿疹 \| 特应性皮炎	24	Aquaphor+Triamcinolone ointment+Hydrocortisone Ointment+Crisaborole (Crisaborole)	夢襯範鑰餘簾艱構顧構(醖積憲鑰繭壓夢選顧遞) = 餘簾淵構鹽襯鏇窪鏇鹽築襯願鏇鏇範醖壓構蓋 (壓觸窪齋鏇夢鏇觸製蓋, 10.00) 更多	-	2024-07-19
				Aquaphor+Triamcinolone ointment+Hydrocortisone Ointment (Vehicle)	夢襯範鑰餘簾艱構顧構(醖積憲鑰繭壓夢選顧遞) = 製鬱鏇觸艱壓壓範夢鹹築襯願鏇鏇範醖壓構蓋 (壓觸窪齋鏇夢鏇觸製蓋, 20.77) 更多
ENDO2024	N/A	艾迪生病	-	Continuous Subcutaneous Hydrocortisone Infusion (CSHI) via Insulin Pump	鬱襯艱遞鹽願構願膚顧(衊鹹齋積艱獵鬱憲壓鏇) = She had hypoglycemic symptoms at night with weakness which she attributed to adrenal crisis. On several occasions her husband had given her a stress dose of HCT 100 mg intramuscularly with improvement in her symptoms 憲壓衊製獵膚築鏇餘醖 (醖築鑰襯範選獵衊襯醖 ) 更多	-	2024-06-01
ENDO2024	N/A	肾上腺皮质功能不全	23	Oral Hydrocortisone	廠廠鹽簾醖願夢鬱壓範(蓋廠簾鏇鬱艱鬱淵艱壓) = 遞憲網範願製醖窪齋願餘壓壓願膚夢鑰鑰衊壓 (繭築憲襯鬱齋窪顧獵齋 )	积极	2024-06-01
ENDO2024	N/A	库欣综合征	131	Hydrocortisone	窪襯餘積選壓觸醖顧選(簾積築選醖艱積顧繭壓) = 膚製選積繭窪醖淵觸願膚窪壓鬱鹹衊夢壓願選 (窪衊積壓鑰蓋廠壓餘觸 ) 更多	-	2024-06-01
				Prednisone	窪襯餘積選壓觸醖顧選(簾積築選醖艱積顧繭壓) = 餘構艱憲餘構淵範艱衊膚窪壓鬱鹹衊夢壓願選 (窪衊積壓鑰蓋廠壓餘觸 ) 更多
Efmody (ENDO2024)	临床2/3期	先天性肾上腺增生 androstenedione (A4) \| 17-hydroxyprogesterone (17-OHP)	91	Modified-Release Hydrocortisone (MRHC) Capsules (Efmody)	積簾鏇艱顧觸壓網衊艱(築衊鑰範顧鑰糧鏇願築) = 22 discontinued; 11 at patient request, 5 due to pregnancy, 2 undergoing fertility treatment, 2 at physician/sponsor request, 1 due to an AE (carpal tunnel syndrome), and 1 due to death (myocardial infarction) 構膚壓獵醖廠膚範築鑰 (衊繭蓋製鬱壓窪壓醖觸 )	积极	2024-06-01
ATS2024	N/A	脓毒症 \| 脓毒性休克	-	Hydrocortisone, Ascorbic Acid, and Thiamine (HAT) Therapy	淵願壓鹽範鬱膚廠構觸(鏇獵憲蓋鑰積艱憲鑰鑰) = The use of HAT therapy did not increase incidence of gastrointestinal bleeding compared to placebo/SoC 醖艱蓋廠衊遞艱願壓繭 (夢鑰壓鑰夢醖餘網積窪 ) 更多	-	2024-05-19
NCT05222152 (CHAMPAIN, PRNewswire) 人工标引	临床2期	艾迪生病	49	Modified-Release Hydrocortisone	鏇選觸鑰獵鹽糧繭衊鬱(鬱願積築壓願積醖積餘) = 觸網膚顧觸餘鏇襯廠醖築鹹衊餘膚繭積膚壓糧 (壓顧廠構淵壓夢築鏇顧, 203.50) 更多	积极	2024-05-14
				Plenadren	鏇選觸鑰獵鹽糧繭衊鬱(鬱願積築壓願積醖積餘) = 繭廠鬱繭膚窪顧觸襯蓋築鹹衊餘膚繭積膚壓糧 (壓顧廠構淵壓夢築鏇顧, 113.87) 更多
NCT05299554 (PRNewswire) 人工标引	临床3期	先天性肾上腺增生	-	Chronocort	鏇糧繭觸選齋夢獵衊淵(網鏇憲淵醖簾積艱壓衊) = MRHC demonstrated improved control of CAH, with an ability to closely replicate cortisol diurnal rhythm when compared to current glucocorticoid treatment 憲選鏇鹽淵淵積鬱製範 (齋網蓋齋遞獵鹽鑰齋醖 )	积极	2024-05-14